Document is current

Article History

Received: 2 April 2023

Accepted: 5 September 2023

First Online: 29 September 2023

Competing interests

: A.V.S. MD MS: Advisory board: Taiho Oncology, Institutional research funding: Natera Pvt. Ltd. F.J. MD PHD: research support from Astex, Novartis, BioMed Valley Discoveries, Fore Biotherapeutics, Deciphera, Bristol Myers Squibb, Asana, IDEAYA Biosciences, Sanofi, Merck, F-star, JSI InnoPharm, BioXcel, Lilly, Bicara Therapeutics, PureTech Health, FUJIFILM Pharmaceuticals, SOTIO, Synlogic, NextCure, and Hutchinson MediPharma; served on the scientific advisory boards of IDEAYA Biosciences, Synlogic, SOTIO, PureTech Health, Deciphera, Crown Bioscience, Asana, Fore Biotherapeutics, Novartis, Bicara Therapeutics, and PegaOne; was a paid consultant for Mersana Therapeutics, Flame Biosciences, Cardiff Oncology, MedinCell, and ImmunoMet Therapeutics; holds a leadership position in Monte Rosa Therapeutics; has an ownership interest in Monte Rosa Oncology and Cardiff Oncology. H.-Z.C. MD PHD: 1. Consultant and speaker for Jazz Pharmaceuticals. Consultant for Biological Dynamics. B.G. MD: Consultant: Ipsen, Bristol Myers Squibb, Foundation Medicine, Taiho Oncology, BTG (Boston Scientific), Roche/Genentech, Pfizer. Research Support: Glyconex (Inst), Helix (Inst), Pfizer, Foundation Medicine (Inst), Roche/Genentech (Inst), Hoffman La-Roche (Inst), Taiho Oncology (Inst), Boehringer Ingelheim (Inst), Toray, NGM Biopharma, Hutchison Medipharma, Mirati Therapeutics, Sirnamomics (Inst), Trishula Therapeutics (Inst), Gritstone BIo (Inst). Stock Ownership: XBiotech. S.K. MD: Research contracts with ACT Genomics, Sysmex, Konica Minolta, OmniSeq, and Personalis; Speaker’s fees from Bayer and Roche; and personal fees from CureMatch, Foundation Medicine, Medpace, NeoGenomics, and Pfizer. R.K. MD: Leadership: CureMatch, CureMetrix Stock and Other Ownership Interests: CureMatch, IDbyDNA, CureMetrix. Honoraria: Roche, EUSA Pharma, NeoGenomics Laboratories, Biocom, NeoMed, LEK, AACR, Chugai Pharma USA, Wiley, Merck, Pfizer, Foundation Medicine, Turning Point Therapeutics, Bicara Therapeutics. Consulting or Advisory Role: Actuate Therapeutics, Loxo, XBiotech, NeoMed, Roche, Gaido, Soluventis, Pfizer, Merck, Turning Point Therapeutics, TD2/ Volastra, Bicara Therapeutics, AstraZeneca, Biological Dynamics, Daiichi Sankyo, Eisai, EOM Pharmaceuticals, Iylon, Prosperdtx. Speakers’ Bureau: Roche, NeoGenomics Laboratories. Research Funding: Guardant Health (Inst), Sequenom (Inst), Merck Serono (Inst), Genentech (Inst), Pfizer (Inst), Foundation Medicine (Inst), Incyte (Inst), Konica Minolta (Inst), Grifols (Inst), OmniSeq (Inst), Debiopharm Group (Inst), Boehringer Ingelheim (Inst), Top Alliance BioScience (Inst), Takeda (Inst), MedImmune (Inst), Biological Dynamics (Inst). Travel, Accommodations, Expenses: Target Cancer, NCI SWOG Other Relationship: R.K. receives research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc, Biological Dynamics, Caris, Datar Genomics, EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc and IDbyDNA; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. The other authors declare no competing interests.